CN101851618B - Modified small interfering RNA and preparation method thereof - Google Patents

Modified small interfering RNA and preparation method thereof Download PDF

Info

Publication number
CN101851618B
CN101851618B CN200910081144.3A CN200910081144A CN101851618B CN 101851618 B CN101851618 B CN 101851618B CN 200910081144 A CN200910081144 A CN 200910081144A CN 101851618 B CN101851618 B CN 101851618B
Authority
CN
China
Prior art keywords
fragment
modification
small rna
nucleotide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200910081144.3A
Other languages
Chinese (zh)
Other versions
CN101851618A (en
Inventor
梁子才
杜权
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomics Biotechnologies Co Ltd
Original Assignee
Biomics Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomics Biotechnologies Co Ltd filed Critical Biomics Biotechnologies Co Ltd
Priority to CN200910081144.3A priority Critical patent/CN101851618B/en
Priority to CN201310052144.7A priority patent/CN103184222B/en
Priority to PCT/CN2010/000405 priority patent/WO2010111891A1/en
Priority to EP10757994.8A priority patent/EP2415869A4/en
Priority to US13/262,702 priority patent/US8563710B2/en
Publication of CN101851618A publication Critical patent/CN101851618A/en
Application granted granted Critical
Publication of CN101851618B publication Critical patent/CN101851618B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a modified small interfering RNA, which comprises a first fragment and a second fragment, wherein the first fragment and the second fragment can form a double-chain area; the first fragment comprises at least one continuous UA sequence; the second fragment comprises at least one continuous UA sequence which is complementary to the UA sequence of the first fragment; the UA sequence of the first fragment and the UA sequence of the second fragment form a UA/UA locus; and at least one nucleotide at the UA/UA locus is modified, and the modification makes the stability of the modified small interfering RNA higher than that of an unmodified small interfering RNA. In the invention, the improvement in the serum stability of the modified small interfering RNA can be achieved with a small amount of modification introduced, so the potential cell toxicity of the modified small interfering RNA molecules and the influences of the modification on the biologic activity of the small interfering RNA are reduced.

Description

Small RNA of a kind of modification and preparation method thereof
Technical field
The present invention relates to small RNA of a kind of modification and preparation method thereof.
Background technology
RNA disturbs (RNA interference, RNAi) to be closed homogenic expression or make the phenomenon of this genetic expression silence in mRNA level by double-stranded RNA (double-strandedRNA, dsRNA) molecule.RNA perturbation technique is called again Knockdown (knock-down) or gene silencing (gene silencing) visually, it is a kind of typical post-transcriptional gene regulation method, claim again PTGS (post-transcriptional gene silencing, PTGS).The report that relevant RNA disturbs the earliest appears at nineteen ninety, report the RNA interference phenomenon in transgenic plant by two different research groups simultaneously, in nearly all eukaryotes such as nematode, fruit bat, zebra fish and mouse, observed RNA interference phenomenon again later.1999, Hamilton and Baulcombe detected that length is the RNA fragment of 21-25 Nucleotide in the plant that RNA interference occurs, and it is necessary that these RNA segments are proved to be RNA interference, is called as small molecule interference nucleic acid (siRNA).The silencing complex (RNA-inducedsilencing complex, RISC) of the relevant enzyme of double-stranded siRNA and cell source and Protein formation RNA induction.In RNA interfering process, the positive-sense strand in double-stranded siRNA is excluded from complex body, and antisense strand instructs RISC to be attached to the homologous site of said target mrna, then by the rnase iii degraded said target mrna in mixture, thereby closes the expression of target gene.
But, due to the less stable of small molecule interference nucleic acid (siRNA), in vivo easily by nuclease degradation, therefore people carry out chemically modified to synthetic siRNA, to increase the serum stability of siRNA, thereby effectively suppress the expression of goal gene.
At present, due to the people's degradation process in serum and enough understandings of mechanism shortage to siRNA, can only rely on experience separately to select randomly the multiple Nucleotide in siRNA molecule to carry out chemically modified.Modify the tactful serum stability that can improve well siRNA molecule although this, but owing to lacking theoretical guidance, conventionally in siRNA molecule, introduced excessive modification, increase the cytotoxicity of the siRNA after modifying, and reduced under many circumstances the biologic activity of siRNA, thereby restrict siRNA after modifying application in vivo.
In addition, in siRNA, in Nucleotide, introduce blindly a large amount of ways of modifying, also limited some and there is better stabilising effect, but the application of the relatively large modifying method of cytotoxicity in studying in vivo.
Therefore, design pointed modification protocols, realizing optimum stability object by minimum modification is current problem in the urgent need to address.
Summary of the invention
Thereby the object of the invention is to overcome and in the modification protocols of existing siRNA, have the large problem of small RNA cytotoxicity that a large amount of modifications causes the modification obtaining of introducing blindly, provide that a kind of serum is stable, small RNA that have good biological activity and the modification that cytotoxicity is lower, and the preparation method of this small molecule interference nucleic acid.
The invention provides a kind of small RNA of modification, it comprises the first fragment and the second fragment, and described the first fragment and the second fragment can form double-stranded region, described the first fragment comprises at least one continuous UA sequence, the continuous UA sequence of the UA sequence complementation that described the second fragment comprises at least one and described the first fragment, the UA sequence of described the first fragment and the UA sequence of described the second fragment form UA/UA site, wherein, at least one Nucleotide in described UA/UA site is through modifying, this modification makes the stability of the small RNA of modifying higher than the small RNA of unmodified.
The present invention is by carrying out specific modification to UA/UA site, thereby in the situation that only introducing a small amount of modification, can reach the object of the serum stability that increases the small RNA after modifying, thereby reduce the potential cytotoxicity of the small RNA molecule after modifying, and modified the impact of the biologic activity on small RNA.
Embodiment
The small RNA of modification provided by the invention, it comprises the first fragment and the second fragment, and described the first fragment and the second fragment can form double-stranded region, described the first fragment comprises at least one continuous UA sequence, the continuous UA sequence of the UA sequence complementation that described the second fragment comprises at least one and described the first fragment, the UA sequence of described the first fragment and the UA sequence of described the second fragment form UA/UA site, wherein, at least one Nucleotide in described UA/UA site is through modifying, this modification makes the stability of the small RNA of modifying higher than the small RNA of unmodified.
The present inventor has carried out careful research to small RNA molecule degradation process in vivo, the in the situation that of finding only to introduce a small amount of modification in UA/UA site, can improve the stability of the small RNA molecule of modification, greatly reduce owing to introducing randomly the cytotoxicity that a large amount of modifications causes highlyer, and modify the impact of the biologic activity on small RNA.
According to the present invention, described " the first fragment " refers to the nucleotide fragments having with the sequence of all or part of homology of sequence of genes encoding chain, and described " the second fragment " refers to the nucleotide fragments having with the sequence of the sequence complementation of genes encoding chain.Described " complementation " refers to that two Nucleotide can match under hybridization conditions, for example, between VITAMIN B4 (A) and thymus pyrimidine (T) or uridylic (U), can match, and pairing between cytosine(Cyt) (C) and guanine (G).
According to the present invention, the target of described small RNA molecule can be range gene, for example, can will there is gene to be analyzed as target in intracellular function, also can be using the gene that need to suppress its expression as target, for example, can using to disease or disorderly relevant gene as target, as the gene on oncogene, virogene, surface of cell membrane acceptor gene, nuclear receptor gene or cell signaling path etc.Those skilled in the art is according to its target gene, can design and obtain small RNA molecule (siRNA), for example, by the target sequence of goal gene or goal gene, the sequence number in NCBI Genbank is inputted various small RNAs and is designed program, as Insert Design Tool for the shRNAVectors (Ambion), shRNA Explorer (Gene Link), siDirect (Yuki Naito et al.University of Tokyo), SiRNA at Whitehead (Whitehead Institute for BiomedicalResearch), BLOCK-iT RNAi Designer (invitrogen), RNAi Design (IDT), RNAiExplorer (Gene Link), siRNA Target Finder (Ambion), or siSearch (StockholmBioinformatics Center) etc., this is designed program will be according to the principle of design of planner's requirement and siRNA, for provided gene or sequences Design siRNA.And some program can be done full genome or mRNA transcribes the homology analysis of group to the siRNA designing, thereby designs target gene or the special siRNA of target sequence.The above-mentioned siRNA mentioning designs program and the principle that relates to is conventionally known to one of skill in the art, and its full content is incorporated herein by reference in the lump at this.
According to the present invention, the small RNA of described modification can comprise multiple UA/UA site, and at least one Nucleotide in the plurality of UA/UA site is through modifying.
In addition,, in the small RNA of described modification, the Nucleotide in described UA/UA site, other Nucleotide is not through modifying.In this case, not only can improve the small RNA of described modification stability, maintain its biological activity, can also make the modification quantity of introducing in the small RNA molecule of modifying minimize, thereby reduce the cytotoxicity of modifying the small molecule interference nucleic acid causing further.
Under preferable case, in the UA/UA site of the small RNA of described modification, only has a uridylate through modifying.The present inventor is surprised to find that, as long as a uridylate in described UA/UA site is modified, just can improve the stability of the small RNA of modification, and maintain its biological activity, in this case, can make the modification quantity of introducing in the small RNA of modifying minimize, thereby further reduce the cytotoxicity of modifying the small molecule interference nucleic acid causing.
According to the present invention, the small RNA of described modification can be that single chain molecule can be also duplex molecule.
In the time that the small RNA of described modification is single chain molecule, the complementary region between described the first fragment and the second fragment forms double-stranded region.
In the time that the small RNA of described modification is duplex molecule, the small RNA of this modification comprises positive-sense strand and antisense strand, and described positive-sense strand can be continuous nucleotide chain, can be also discontinuous nucleotide chain; Described antisense strand is continuous nucleotide chain.
According to an aspect of the present invention, the small RNA of modification provided by the invention comprises positive-sense strand and antisense strand, and described positive-sense strand and antisense strand be continuous nucleotide chain, and described first section is positioned at positive-sense strand, and described the second fragment is positioned at antisense strand.
According to another aspect of the present invention, the small RNA of modification provided by the invention comprises positive-sense strand and antisense strand, and described positive-sense strand is the discontinuous nucleotide chain that comprises two or more positive-sense strand parts; Described antisense strand is continuous nucleotide chain; Described first section is positioned at one or more positive-sense strand parts, and described the second fragment is positioned at antisense strand.
In the present invention, term " positive-sense strand " refers in the time that the small RNA of described modification is duplex molecule, there is the nucleotide fragments with the sequence of all or part of homology of sequence of genes encoding chain, described " antisense strand " refer in the time that the small RNA of described modification is duplex molecule, has the nucleotide fragments with the sequence of the sequence complementation of genes encoding chain.And when the small RNA of described modification is duplex molecule and described positive-sense strand and antisense strand while being continuous nucleotide chain, term " positive-sense strand " and " the first fragment " can be exchanged use, term " antisense strand " and " the second fragment " can be exchanged use.
In the present invention, term " positive-sense strand part " refers in the time that described positive-sense strand is discontinuous Nucleotide, for forming a part of nucleotide chain of positive-sense strand; In described positive-sense strand, the total length of all positive-sense strand parts of this positive-sense strand and described positive-sense strand equal in length, and in the time comprising UA/UA site in described positive-sense strand part, term " positive-sense strand part " can exchange use with " the first fragment ".
According to the present invention, the small RNA of described modification can be made up of ribonucleotide, can be also the hybrid molecule that comprises ribonucleotide and at least one deoxyribonucleotide.
According to the present invention, term " cytotoxicity " refers to the toxic action to cell causing due to nucleic acid molecule is modified.
In the present invention, the mode of described modification is conventionally known to one of skill in the art, and for example, the chemically modified that the present invention carries out described small molecule interference nucleic acid is following one or more:
(1) to connecting the modification of the phosphodiester bond of Nucleotide in the nucleotide sequence of described small molecule interference nucleic acid;
(2) to ribose in the nucleotide sequence of described small molecule interference nucleic acid modification;
(3) modification to base in the nucleotide sequence of described small molecule interference nucleic acid.
The modification of described phosphodiester bond refers to modifies the oxygen in phosphodiester bond, comprises thiophosphoric acid modification (Phosphorthioate) and borine phosphate modified (Boranophosphate).As shown in the figure respectively with the oxygen in sulphur and borine displacement phosphodiester bond.Two kinds of modifications can stable micro-molecular interfere RNA structure, keep high specific and the high-affinity of base pairing.And the hydrophobicity of the small RNA of borine phosphate modified is strong, be easy to form hydrated protein in blood plasma, to the toxic side effect of human body lower than thiophosphatephosphorothioate.
Figure G2009100811443D00061
Thiophosphoric acid is modified borine phosphate modified
Described ribose is modified the modification referring to hydroxyl in Nucleotide pentose (2 '-OH).The hydroxy position of ribose introduce some substituting group as methoxyl group or fluorine after, make serum rnase small RNA not easy to identify, increased the stability of small RNA.Make small RNA there is the performance of stronger opposing nuclease hydrolysis.The modification of hydroxyl in Nucleotide pentose is comprised to 2 '-fluorine modification (2 '-fluro modification); 2 '-oxygen methyl is modified (2 '-OME); 2 '-methoxyethyl is modified (2 '-MOE); 2,4 '-dinitrophenol(DNP) is modified (2 '-DNP modification); Lock nucleic acid (LNA); 2 '-amido modified (Amina modification); (2 '-Deoxy modification) etc. modified in 2 '-deoxidation.
2 '-fluorine is modified 2 '-oxygen methyl and is modified
Figure G2009100811443D00072
2 '-methoxyethyl is modified 2,4 '-dinitrophenol(DNP) and is modified
Figure G2009100811443D00073
Lock nucleic acid 2 '-amido modified
Figure G2009100811443D00074
2 '-deoxidation is modified
Described base modification refers to be modified the base of Nucleotide, if 5 '-bromouracil (5 '-bromo-uracil) and 5 '-iodouracil (5 '-iodo-uracil) modification of introducing bromine or iodine in 5 sites of uridylic are the normal base modification methods using, other also have N3-methyl uracil (N3-methyl-uracil) to modify, 2,6-diaminopurine (2,6-diaminopurine) modification etc.
Figure G2009100811443D00081
5 '-bromouracil 5 '-iodouracil
Figure G2009100811443D00082
N3-methyl uracil 2,6-diaminopurine
Under preferable case, described in be modified to the modification to 2 '-OH of ribose in the nucleotide sequence of described small molecule interference nucleic acid.More preferably, the 2 '-OH that is modified to ribose in the nucleotide sequence of described small molecule interference nucleic acid described in is replaced by methoxyl group or fluorine.Above-mentioned modification all can increase the serum stability of described small RNA, strengthens its resistivity to the hydrolysis of serum nuclease.
The present invention also provides a kind of preparation method of small RNA of modification, wherein, the method comprises: according to the nucleotide sequence of the small RNA of unmodified, and use is through the Nucleotide of corresponding position in the nucleotide sequence of the small RNA of the alternative described unmodified of modified nucleotide, carry out the small RNA of synthetic modification, make the small RNA of the modification obtaining comprise the first fragment and the second fragment, and described the first fragment and the second fragment can form double-stranded region, described the first fragment comprises at least one continuous UA sequence, the continuous UA sequence of the UA sequence complementation that described the second fragment comprises at least one and described the first fragment, the UA sequence of described the first fragment and the UA sequence of described the second fragment form UA/UA site, wherein, at least one Nucleotide in described UA/UA site is through modifying, this modification makes the stability of the small RNA of modifying higher than the small RNA of unmodified.
According to an aspect of the present invention, the preparation method of the small RNA of described modification provided by the invention can comprise: according to the nucleotide sequence of the small RNA of unmodified, and use is through the Nucleotide of corresponding position in the nucleotide sequence of the small RNA of the alternative described unmodified of modified nucleotide, carry out the small RNA of synthetic modification, make the small RNA of the modification obtaining comprise multiple UA/UA site, and at least one Nucleotide in the plurality of UA/UA site is through modifying.
According to another aspect of the present invention, the preparation method of the small RNA of described modification provided by the invention can comprise: according to the nucleotide sequence of the small RNA of unmodified, and use is through the Nucleotide of corresponding position in the nucleotide sequence of the small RNA of the alternative described unmodified of modified nucleotide, carry out the small RNA of synthetic modification, make in the small RNA of the modification obtaining, Nucleotide in described UA/UA site, other Nucleotide is not through modifying.And, under preferable case, in the UA/UA site of the small RNA of the modification obtaining, only have a uridylate through modifying.
In the present invention, the structure of the small RNA of modification provided by the invention is conventionally known to one of skill in the art, can be the structure that exists of various small RNAs.
For example, according to an aspect of the present invention, the small RNA of modification provided by the invention can be the single chain molecule of hairpin structure, and the complementary region between described the first fragment and the second fragment forms double-stranded region.
According to another aspect of the present invention, the small RNA of modification provided by the invention can comprise positive-sense strand and antisense strand, and described positive-sense strand and antisense strand are continuous nucleotide chain, and described first section is positioned at positive-sense strand, and described the second fragment is positioned at antisense strand.
According to another aspect of the present invention, the small RNA of modification provided by the invention can comprise positive-sense strand and antisense strand, and described positive-sense strand is the discontinuous nucleotide chain that comprises two or more positive-sense strand parts; Described antisense strand is continuous nucleotide chain; Described first section is positioned at one or more positive-sense strand parts, and described the second fragment is positioned at antisense strand.
According to another aspect of the present invention, the small RNA of modification provided by the invention can be the hybrid molecule for comprising ribonucleotide and at least one deoxyribonucleotide.
In the present invention, the method of synthetic small RNA can be the synthetic method of the small RNA of various routines, or it is synthetic that the synthetic biotech company of nucleic acid is specialized in trust, as entrusted Shanghai JiMa pharmacy Technology Co., Ltd (GenePharma), Rui Bo bio tech ltd, Guangzhou or handsome Bioisystech Co., Ltd (invitrogen) to synthesize.
In general, comprise following Four processes for the synthesis of the method for small RNA: (1) oligomerization ribonucleotide synthetic; (2) deprotection; (3) purifies and separates; (4) desalination.
For example, there are the concrete steps of the small RNA chemosynthesis of nucleotide sequence shown in SEQ ID NO:1 as follows:
(1) oligomerization ribonucleotide is synthetic: at automated DNA/RNA synthesizer (for example, AppliedBiosystems EXPEDITE8909) the upper RNA that sets synthetic 1 mmole, the coupling time of simultaneously setting each circulation is 10-15 minute, initiator be solid phase connect 5 '-O-to dimethoxy-thymidine upholder, first circulates in and on solid support, connects a base, then in the n time (19 >=n >=2) circulation, in the base connecting the n-1 time circulation, connect a base, repeat this circulation until complete the synthetic of whole nucleotide sequences.
(2) deprotection
The solid support that is connected with small RNA is joined in test tube, and in this test tube, add the ethanol/ethamine (volume ratio is 1: 3) of 1 milliliter, then sealing, be placed in 55-70 ℃ of incubator, hatch 2-30 hour, fech connection has the solid support of small RNA and with distilled water drip washing 2 times (each 1 milliliter), collects elutriant, and at room temperature dry 30 minutes.Then, add the tetrahydrofuran solution (1M) of 1 milliliter of tetrabutyl ammonium fluoride, room temperature is placed 4-12 hour, then adds 2 milliliters of ethanol, and collecting precipitation obtains the crude product of small RNA.
(3) purifies and separates
It is in the ammonium acetate solution of 1 mole/milliliter that the crude product of the small RNA obtaining is dissolved in to 2 ml concns, then separates by C18 high pressure liquid chromatography, obtains the small RNA product of purifying.
(4) desalination
Be small RNA product 2-4 time (each 2 milliliters) of the aqueous ethanolic solution washing purifying of 75 % by weight by concentration, remove salt, and dry under room temperature.Then by oligomerization Yeast Nucleic Acid mixed dissolution (10mM Tris in the damping fluid of 1-2 milliliter of positive-sense strand and antisense strand, pH=7.5-8.0,50mM NaCl), this solution is heated to 95 ℃, then slowly this solution is cooled to room temperature, and maintain room temperature 16-22 hour, obtain the solution that contains small RNA.
Above provide the object of numerous embodiments only for exemplarily the present invention will be described, rather than in order to limit the scope of the invention.
Further illustrate the present invention below in conjunction with embodiment, unless stated otherwise, the present invention's reagent used, substratum are commercial goods.
Embodiment 1
The gene of choosing in following table is target gene, and entrusts the siRNA in the synthetic table 1-127 of Shanghai JiMa pharmacy Technology Co., Ltd (GenePharma).
Embodiment 2
SiRNA shown in his-and-hers watches 1-127 carries out serum stability detection respectively by the following method, gene silencing efficiency detects and cytotoxicity detects:
1. serum stability detects
Be the modifying small RNA with different chemical and join and contain in 4 μ L foetal calf serums and 32 μ L 1 × PBS solution of unmodified of 20 μ M by 4 μ L concentration, the final concentration of serum is 10%; After reaction system being hatched to the regular hour under 37 ℃ of conditions, sample, be generally 0,3 and 6 hour; Get 10 μ L samples at every turn and carry out liquid nitrogen flash freezer, to end immediately the effect of serum nuclease to siRNA, then that Sample preservation is for subsequent use under-80 ℃ of conditions.
The polyacrylamide gel of configuration 20%, mixes the sample-loading buffer of 3 μ L (30mM EDTA, 36% glycerine, 0.06% tetrabromophenol sulfonphthalein) then loading, electrophoresis under the constant current conditions of 80mA with the degraded sample of siRNA.After electrophoresis finishes, carry out taking a picture after the dyeing of 10 minutes with 1 × Sybr Gold dyestuff (Invitrogen, Cat.11494), result is as shown in table 1-127.
2. gene silencing efficiency detects
The human embryonic kidney cell (HEK293) that will cultivate in the DMEM substratum (10%FBS, 2mM L-glutaminate, the Streptomycin sulphate of the penicillin of 100 units per ml and 100 μ g/ml) is inoculated in 24 orifice plates (1 × 10 5cell/0.5ml substratum/hole).After 24 hours, when the degrees of fusion of cell is 50% left and right, substratum is changed to Opti-MEM substratum (Gibco company) until Growth of Cells.Then control plasmid (the Promega company of restructuring Photinus pyralis LUC reporter plasmid and pRL-TK (coding Renilla luciferase) of target site will be separated with siRNA, Madison WI, USA) pass through Lipofectamine 2000 (Invitrogen company with the siRNA of chemosynthesis, the U.S.) carry out cell transfecting, every hole is containing 0.17g recombinant plasmid and 0.017g pRL-TK control plasmid, and the final concentration of siRNA is 13nM.Three multiple holes of every kind of parallel transfection of siRNA, with two kinds of reporter plasmids of the same amount of a transfection, three multiple holes of not transfection siRNA in contrast.After 4 hours, again transfection medium is changed into 1ml DMEM substratum (10%FBS, 2mM L-glutaminate, the Streptomycin sulphate of the penicillin of 100 units per ml and 100 μ g/ml).Harvested cell after 24 hours, with 10 μ l cell pyrolysis liquid cells, utilize Relative luciferase activity assay system (Dual-Luciferase Assay System, Promega company) and microplate reader (Novostar, BMG Labtechnologies GmbH, Germany) activity of two kinds of luciferases of mensuration, using the expression amount of the reporter gene in the hole of untransfected siRNA as standard control, calculate the silence efficiency of siRNA to target site by following formula, result is as shown in table 2.Every kind of siRNA tests parallel 3 the multiple holes of doing at every turn, and each experiment repeats 2 times, and result is as shown in table 1-127.
Silence efficiency=(expression amount/experimental group Renilla luciferase expression amount of experimental group Firefly luciferase)/(expression amount/control group Renilla luciferase expression amount of control group Firefly luciferase)
The cytotoxicity of 3, modifying siRNA detects
The human embryonic kidney cell (HEK293) that will cultivate in the DMEM substratum (10%FBS, 2mM L-glutaminate, the Streptomycin sulphate of the penicillin of 100 units per ml and 100 μ g/ml) is inoculated in 24 orifice plates (1 × 10 5cells/well); After 24 hours, when the degrees of fusion of cell is 50% left and right, substratum is changed to Opti-MEM substratum (Gibco company) until Growth of Cells; Then the siRNA of chemosynthesis is passed through to Lipofectamine 2000 (Invitrogen company, the U.S.) carry out cell transfecting, the final concentration of siRNA is 13nM, and holes are answered in every kind of three of parallel transfection of siRNA, answer hole in contrast without three transfections of siRNA; After 4 hours, again transfection medium is changed into 1ml DMEM substratum (10%FBS, 2mML-glutamine, the Streptomycin sulphate of the penicillin of 100 units per ml and 100 μ g/ml); After 24 hours, suck nutrient solution, wash once with PBS, every hole adds 1ml PBS and 10 μ l MTT (tetrazolium bromide) dye liquors, at 37 ℃ of 5%CO 2cO2gas incubator in cultivate 4~6 hours; Every hole adds 0.1ml acidifying Virahol, on vibrator, vibrates and mixes, and allows reduzate fully dissolve; Enzyme-linked immunosorbent assay instrument is measured each hole, 570nm place A value, and calculates inhibitory rate of cell growth according to following formula, and result is as shown in table 1-127.
Inhibitory rate of cell growth (%)=(control group average A value-experimental group average A value)/control group average A value × 100%.
Table 1
Figure G2009100811443D00151
Table 2
Figure G2009100811443D00161
Table 3
Figure G2009100811443D00162
Figure G2009100811443D00181
Table 4
Table 5
Figure G2009100811443D00183
Table 6
Figure G2009100811443D00191
Table 7
Figure G2009100811443D00192
Table 8
Table 9
Figure G2009100811443D00201
Table 10
Figure G2009100811443D00202
Table 11
Figure G2009100811443D00203
Table 12
Figure G2009100811443D00211
Table 13
Table 14
Figure G2009100811443D00213
Table 15
Figure G2009100811443D00221
Table 16
Figure G2009100811443D00222
Table 17
Figure G2009100811443D00223
Table 18
Figure G2009100811443D00231
Table 19
Figure G2009100811443D00232
Table 20
Figure G2009100811443D00233
Table 21
Figure G2009100811443D00241
Table 22
Figure G2009100811443D00242
Table 23
Figure G2009100811443D00243
Table 24
Figure G2009100811443D00251
Table 25
Figure G2009100811443D00252
Table 26
Figure G2009100811443D00253
Table 27
Figure G2009100811443D00261
Table 28
Figure G2009100811443D00262
Table 29
Figure G2009100811443D00263
Table 30
Figure G2009100811443D00271
Table 31
Figure G2009100811443D00272
Table 32
Table 33
Figure G2009100811443D00281
Table 34
Figure G2009100811443D00282
Table 35
Figure G2009100811443D00283
Table 36
Figure G2009100811443D00291
Table 37
Figure G2009100811443D00292
Table 38
Figure G2009100811443D00293
Table 39
Figure G2009100811443D00301
Table 40
Figure G2009100811443D00302
Table 41
Figure G2009100811443D00303
Table 42
Figure G2009100811443D00311
Table 43
Figure G2009100811443D00312
Table 44
Figure G2009100811443D00313
Table 45
Figure G2009100811443D00321
Table 46
Figure G2009100811443D00322
Table 47
Figure G2009100811443D00323
Table 48
Figure G2009100811443D00331
Table 49
Figure G2009100811443D00332
Table 50
Figure G2009100811443D00333
Table 51
Table 52
Figure G2009100811443D00342
Table 53
Figure G2009100811443D00343
Table 54
Figure G2009100811443D00351
Table 55
Figure G2009100811443D00352
Table 56
Figure G2009100811443D00353
Table 57
Figure G2009100811443D00361
Table 58
Table 59
Figure G2009100811443D00363
Table 60
Figure G2009100811443D00371
Table 61
Table 62
Table 63
Table 64
Figure G2009100811443D00382
Table 65
Figure G2009100811443D00383
Table 66
Table 67
Table 68
Table 69
Figure G2009100811443D00401
Table 70
Figure G2009100811443D00402
Table 71
Figure G2009100811443D00403
Table 72
Figure G2009100811443D00411
Table 73
Figure G2009100811443D00412
Table 74
Table 75
Figure G2009100811443D00421
Table 76
Figure G2009100811443D00422
Table 77
Table 78
Figure G2009100811443D00431
Table 79
Figure G2009100811443D00432
Table 80
Figure G2009100811443D00433
Table 81
Figure G2009100811443D00441
Table 82
Table 83
Figure G2009100811443D00443
Table 84
Figure G2009100811443D00451
Table 85
Figure G2009100811443D00452
Table 86
Figure G2009100811443D00453
Table 87
Figure G2009100811443D00461
Table 88
Figure G2009100811443D00462
Table 89
Figure G2009100811443D00463
Table 90
Figure G2009100811443D00471
Table 91
Figure G2009100811443D00472
Table 92
Figure G2009100811443D00473
Table 93
Figure G2009100811443D00481
Table 94
Figure G2009100811443D00482
Table 95
Figure G2009100811443D00483
Table 96
Table 97
Figure G2009100811443D00492
Table 98
Table 99
Figure G2009100811443D00501
Table 100
Table 101
Figure G2009100811443D00503
Table 102
Table 103
Figure G2009100811443D00512
Table 104
Figure G2009100811443D00513
Table 105
Figure G2009100811443D00521
Table 106
Figure G2009100811443D00522
Table 107
Figure G2009100811443D00523
Table 108
Figure G2009100811443D00531
Table 109
Figure G2009100811443D00532
Table 110
Table 111
Figure G2009100811443D00541
Table 112
Table 113
Table 114
Figure G2009100811443D00551
Table 115
Figure G2009100811443D00552
Table 116
Figure G2009100811443D00553
Table 117
Figure G2009100811443D00561
Table 118
Figure G2009100811443D00562
Table 119
Table 120
Figure G2009100811443D00571
Table 121
Table 122
Figure G2009100811443D00573
Table 123
Figure G2009100811443D00581
Table 124
Figure G2009100811443D00582
Table 125
Figure G2009100811443D00583
Table 126
Figure G2009100811443D00591
Table 127
Figure G2009100811443D00592
In upper table 1-127:
" A ", " U " that bold-faced letter represents, " G " or " C " Nucleotide of letter representation through modifying;
"+" represents after serum is hatched, the completely dissolve of siRNA master tape, visible significantly degraded band;
" ++ " represents after serum is hatched, though siRNA master tape has degraded but still be high-visible, visible significantly degraded band;
" +++ " represents after serum is hatched, and siRNA master tape is clear has no degraded, has no obvious degraded band.
In addition, from table 1-127, can find out, with compared with the random small RNA of modifying, small RNA provided by the invention is in having improved stability, also reduce significantly the cytotoxicity of small RNA, and the expression inhibiting efficiency on small RNA does not affect substantially, as can be seen here, the present invention is in the situation that only introducing a small amount of modification, can reach the object of the serum stability that increases the small RNA after modifying, thereby reduce the potential cytotoxicity of the small RNA molecule after modifying, and the impact of the biologic activity of modification on small RNA.
SEQUENCE LISTING
<110> Peking University
Small RNA of a <120> modification and preparation method thereof
<130>I10554PKU
<160>10
<170>PatentIn version 3.3
<210>1
<211>1500
<212>DNA
The <213> mankind (Homo sapiens BIC)
<400>1
gccgagcccg ggcccagcgc cgcctgcagc ctcgggaagg gagcggatag cggagccccg 60
agccgcccgc agagcaagcg cggggaacca aggagacgct cctggcactg cagataactt 120
gtctgcattt caagaacaac ctaccagaga ccttacctgt caccttggct ctcccaccca 180
atggagatgg ctctaatggt ggcacaaacc aggaagggga aatctgtggt ttaaattctt 240
tatgcctcat cctctgagtg ctgaaggctt gctgtaggct gtatgctgtt aatgctaatc 300
gtgatagggg tttttgcctc caactgactc ctacatatta gcattaacag tgtatgatgc 360
ctgttactag cattcacatg gaacaaattg ctgccgtggg aggatgacaa agaagcatga 420
gtcaccctgc tggataaact tagacttcag gctttatcat ttttcaatct gttaatcata 480
atctggtcac tgggatgttc aaccttaaac taagttttga aagtaaggtt atttaaaaga 540
tttatcagta gtatcctaaa tgcaaacatt ttcatttaaa tgtcaagccc atgtttgttt 600
ttatcattaa cagaaaatat attcatgtca ttcttaattg caggttttgg cttgttcatt 660
ataatgttca taaacacctt tgattcaact gttagaaatg tgggctaaac acaaatttct 720
ataatatttt tgtagttaaa aattagaagg actactaacc tccagttata tcatggattg 780
tctggcaacg ttttttaaaa gatttagaaa ctggtacttt cccccaggta acgattttct 840
gttcaggcaa cttcagttta aaattaatac ttttatttga ctcttaaagg gaaactgaaa 900
ggctatgaag ctgaattttt ttaatgaaat atttttaaca gttagcaggg taaataacat 960
ctgacagcta atgagatatt ttttccatac aagataaaaa gatttaatca aaaaatttca 1020
tatttgaaat gaagtcccaa atctaggttc aagttcaata gcttagccac ataatacggt 1080
tgtgcgagca gagaatctac ctttccactt ctaagcctgt ttcttcctcc atatggggat 1140
aatactttac aaggttgttg tgaggcttag atgagataga gaattattcc ataagataat 1200
caagtgctac attaatgtta tagttagatt aatccaagaa ctagtcaccc tactttatta 1260
gagaagagaa aagctaatga tttgatttgc agaatattta aggtttggat ttctatgcag 1320
tttttctaaa taaccatcac ttacaaatat gtaaccaaac gtaattgtta gtatatttaa 1380
tgtaaacttg ttttaacaac tcttctcaac attttgtcca ggttattcac tgtaaccaaa 1440
taaatctcat gagtctttag ttgatttaaa ataaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
<210>2
<211>6047
<212>DNA
The <213> mankind (Homo sapiens kazrin)
<400>2
ggggtctcgg cgatcgctgc tcctcctcct ccttctcctc ctcttttttc tcctccgcct 60
cctccccccg ccgcctcgcc accgccgcgg ctagggctgg aggcgccgct gtcattcctg 120
tgccggagga accggcgctg ccggtgcctg ggggtcgggg cgcgggcgaa gccgggccgc 180
ggaggacaca acaggtagag ccgggggtgc ccggccgcgc gccccccgcg catcatgcag 240
ctctttgtca cctctctcgc ccccaggcca aaatcctgag catgatggaa gacaataagc 300
agctcgcgct ccgcatcgat ggggcggtcc agtcggccag ccaggaggtg accaacctgc 360
gagccgaact cacggccacc aaccggagac tggcggaact gagcggcggc ggcggccccg 420
gcccgggccc gggagccgcg gccagcgcct cggcggcggg ggactcggcg gcgacgaaca 480
tggagaaccc ccagcttgga gcgcaagtgc tcctgcggga agaagtgtcg cggctccagg 540
aggaagttca ccttctccgg cagatgaagg agatgttggc gaaggacctg gaggagtcgc 600
agggcggcaa gtcctctgag gtcctctcgg ccaccgagct cagggtccag ctggcccaga 660
aggagcagga gctagccaga gccaaagaag ccttgcaggc catgaaagct gatcggaagc 720
gcttaaaggg cgagaagaca gacctggtga gccagatgca gcagctgtat gccacactgg 780
agagccgcga ggagcagctc cgagacttca tccgcaacta tgagcagcac cgcaaggaga 840
gcgaggatgc ggtcaaagcg ctggccaagg agaaggacct gctggagcgt gagaagtggg 900
agctgcggcg ccaagccaag gaggccacag accacgccac ggcactgcgc tcccagctgg 960
acctcaagga caaccggatg aaggagctgg aggccgagct ggccatggcc aaacagtcct 1020
tagctacgct gaccaaggac gtccccaagc ggcattccct cgccatgccg ggcgagacgg 1080
tgctcaatgg caaccaggag tgggtggtgc aggcggacct cccgctgacc gcagccatcc 1140
ggcagagtca acagactctc taccactcac acccccctca ccctgcggac cggcaagcgg 1200
tcagggtgag cccctgccac tcccggcagc cctctgtcat ctccgacgca tctgccgccg 1260
aaggcgaccg gtcgtccaca ccgagcgaca tcaactcccc tcgacaccgg acacactccc 1320
tctgcaacgg cgacagtccc ggcccagttc agaagaacct gcacaaccct attgtacagt 1380
cactagagga tcttgaagac caaaaacgga aaaagaagaa agagaagatg ggattcggct 1440
ccatctcccg cgtcttcgcc agagggaagc agcggaagtc cctcgacccc ggcctctttg 1500
atgactcgga cagccagtgc agccccacgc ggcagagcct cagcctgtcg gaaggcgagg 1560
agcagatgga ccggctgcag caggtggagc tggtgaggac cacccctatg tcccactgga 1620
aggcgggcac cgtccaggcc tggctggagg tggtgatggc catgcctatg tacgtcaagg 1680
cctgcacgga gaacgtgaag agcgggaagg tgctgctgag cctgagtgac gaggacctgc 1740
agctgggcct tggggtgtgc agctccctgc accggcgcaa gctgcgcctg gccatcgagg 1800
actaccgtga tgccgaggca ggccgcagcc tgtccaaagc tgccgagctg gaccatcact 1860
gggtggccaa ggcctggctg aatgacattg gcctgtccca gtactcccag gcctttcaga 1920
accacctggt tgatgggcgg atgctgaatt ccctgatgaa gcgagacctg gagaagcacc 1980
tgaacgtgtc caagaagttc caccaggtca gcatcctgct ggggatcgag ctgctgtacc 2040
aagtgaactt cagcagggag gccctccagg agcgccgggc ccgctgcgag acgcagaaca 2100
ttgaccccgt ggtgtggacc aaccagcggg tgctcaagtg ggttcgagac atcgacctga 2160
aggagtacgc agacaacctg accaacagcg gcgtccatgg tgctgtgctg gtgctggagc 2220
ccacattcaa tgccgaggcc atggccactg ccctgggcat ccccagtggg aagcacatcc 2280
tccggagaca cctggcagag gagatgagcg ccgtcttcca cccagccaac tccacaggca 2340
tccgggaggc tgagcgtttt ggaacgcccc ctggcagggc ctccagcgtc acgcgggcag 2400
gaaaggagga gaacagcagc ggtctcaagt acaaggctgg ccggctgccc ctggggaaga 2460
taggaagggg cttcagcagc aaagatcccg atttccatga tgactatggc tctcttcaaa 2520
acgaagattg cggagacgat gacccccaga gcaggctgga acagtgccgt ctggaaggct 2580
acaacagcct ggaggtcacc aacgtgtaag gaactggtgg ctccaccaga cccaacgtga 2640
gagacccagg aaggaagaga agccagatgg ccccaggtgt cgttctcact gtacatagcg 2700
gccgcaggct gaggatgtcc cttgctcctg ggcaaaatcc cgatggactc tgcggtttca 2760
gctccacagc gcccaggaga gagaagacac cagcccacct gtcttgggtg ggccatggac 2820
tttcctgttc agctggagat gggcccagag gacctgtcac agtgtccggc cctgcctcca 2880
tccaggatac acaggctcca cctcagagtg accgtcactg tggagcagcc aagcagtccc 2940
tggagcctta aacggagctg ccaaggtggg aggaggccca cagttcccta aaacaccctt 3000
ccggcgggag caggggggac cccaacccca caccccagcg cccagtgcat tggcagagcc 3060
gggtgcagga agtgctgcct cttgccgaga cgtcggacag ggcgggggtt ggggaactct 3120
cggctacagc atcttaccct tgactgagaa cttgggtcct gacttggctc actgaatctc 3180
tcttgggaga atgcaaaatc cttccacctg aaaagctctg tgacacatgg gggtggacgt 3240
attgaagagc tgtttgccga tccacccagg agtggctacg ctgagtgggg agccggtgaa 3300
tgatccgtgc aggagtgggg cttagcagcc acatttctag gagatgcaga tatcctatca 3360
ccagaatgaa agctattggg acaacaggat cggggatgac cgacggcccc atatggtgaa 3420
tctctggcct gtggtttggc tttactgaga ttccaaaccc cactatctgc actccgtgac 3480
agtggtatgg agtgtggcaa tgagtttggg gtctggggca gggaaatgct tgacattgtt 3540
aacccaacaa acctttgttg tgatgtccct gtcacctgaa acataggtga catagctcac 3600
caatgtccta accgagacac aaactccaca gagcaaaatc atttggtatt ggtggggaga 3660
accccagccc ttttcttgac ctgccactgt tatgctgtgt ggcttcttcc cagtggcctc 3720
acctctctgt gcctcgatgt cttcatctac gatacttctg gttccctccc agggacatcg 3780
tgaggattaa cacttgctaa tatctgtaac acaatttgta acctctcagg agacaatggg 3840
aagttatggg gtagctaatt tcccatttac aacacagaaa tgatatagag ctagttcgct 3900
ccaactcttt aggttgaagc agtgtgcaaa aggaagaaaa gaaatgttta atgttcagac 3960
ctgccaagag cctccaacag ggctcaagaa acatataaat cccatgagca cagccttgaa 4020
aaccagtttg actcaagcct tcgggcctca gttcattgac cagatgacag ccacgtgatg 4080
attagggaag gacggatgca ttgcgattct gcttacacat cgggttatca aagcgagtca 4140
cttgttggaa ccatgatgct cgacctcctt caaggccgtt tgcactgggg cttgagtttc 4200
caagattcac aacaggtgtc agcctctgag aaccctcaaa gcgtgtgttc ttcaacctgg 4260
caaattgttt cctctcatgg gggaagccga gctctgatga acttgagaat tacacctctc 4320
tcatgccgaa gaccgtggtg ttccccctaa tgacataaac gcagcctttc ttgctgtctg 4380
agaccaaatg tctagttggt agacaggtgg atgtttggcc tcctaagggc acacttctga 4440
tcctgggccc caggtggtga atctctggca tgtggcttgg ctttgttgag actccaaatt 4500
ccattatctt catgacattc ggcctcatcc atagggtcct gaagctgcag tccacagctc 4560
agaaaggaga ggtgagacct ccctccaacc tggtgccaca ggtctctccc aagccacatc 4620
cagcctggat gacctgggac cccagaaact gccgtttggg aggcagcaac agcaacgtgc 4680
ccaggcaggc agttattccc acagagtgag ccagaattgt agcagggcac ttgaatgcag 4740
agctgatgat ttgaaaccaa cgttcaccca acttgtcaga aatggcactt acatggttcg 4800
atcttgctgg agacaagtgg acaattgggg gtcactggca gagacagtat tgcccaaaat 4860
gttcacagca ggaggccagc aggcctgagg caacacgggc aaccgcgaat gcctcttttg 4920
gtttaaatta tgccatcaca accctctttc acccatgagg ctccccatcc ctgacagcca 4980
ggtgagcatt tggagctggt ttctcaacat gaggatgggt tggttgttaa attaacaacc 5040
tccacagtat cagattgagt gagctttgtc tgctggaaaa acctgaaacg tcaactctgc 5100
ttcaaggtcg gcaagaagaa cagaaggcgg agacttggca gagagactca agctgattgt 5160
cacaggctac agaggggcca gctccagaac agtgaccagc tacatcctgt ccaagcagcc 5220
cgagtgtggt cttggtccct gcagggcaat gtgggcatct ggacctgggg acgatgtgga 5280
tgcacttctt ggaaagctgt tgtagcttgt gcctgtgggt ggagaaggca cctgcctggt 5340
agactctcag ctttctgacc cccaggagcc tctgcgaggc ccctttgtcc ttggctgagc 5400
cggacctttc ttttggaaat ctgtctgtct gttggcatcg ctgttttcag accccaggct 5460
gcagaggagg ggagaagcca cacaacaatc tggacccaat aaagtggaga gaagggcgtc 5520
tctacacagc ccggccagcg tggagggccc caggacaggg acccaaaagc ttgacgtcac 5580
tgaacagggc tgggtactgg cagaacagga agatttggcc agaggtgacc tcagtgttcc 5640
ctccaggggc atccaggccc ctctgacctg gggagaagaa ggcccatgct caggcccacc 5700
tccctcttcc catcagagcc catgcgtcct gggcaccacc acttccactc tgcttttcga 5760
ggctccggag ggctcttcct gctgtgaaag gaaaggagaa gaaagcctgt gggcaatggc 5820
aacctctgag tctggcattc ttgccaatgg ctggccagcg aggagaatct cccgagccct 5880
gacacacaaa ggcattttgt ggctgcagag gaaatgggtt ggctctgaac aaagatgcag 5940
tttctagggc cgtggcccca aatcgcttcc ccgagagtga attttaacac tgtaacaata 6000
aatactactg cacagcactt taaaaaaaaa aaaaaaaaaa aaaaaaa 6047
<210>3
<211>2413
<212>DNA
The <213> mankind (Homo sapiens CDKN1B)
<400>3
cttcttcgtc agcctccctt ccaccgccat attgggccac taaaaaaagg gggctcgtct 60
tttcggggtg tttttctccc cctcccctgt ccccgcttgc tcacggctct gcgactccga 120
cgccggcaag gtttggagag cggctgggtt cgcgggaccc gcgggcttgc acccgcccag 180
actcggacgg gctttgccac cctctccgct tgcctggtcc cctctcctct ccgccctccc 240
gctcgccagt ccatttgatc agcggagact cggcggccgg gccggggctt ccccgcagcc 300
cctgcgcgct cctagagctc gggccgtggc tcgtcggggt ctgtgtcttt tggctccgag 360
ggcagtcgct gggcttccga gaggggttcg ggctgcgtag gggcgctttg ttttgttcgg 420
ttttgttttt ttgagagtgc gagagaggcg gtcgtgcaga cccgggagaa agatgtcaaa 480
cgtgcgagtg tctaacggga gccctagcct ggagcggatg gacgccaggc aggcggagca 540
ccccaagccc tcggcctgca ggaacctctt cggcccggtg gaccacgaag agttaacccg 600
ggacttggag aagcactgca gagacatgga agaggcgagc cagcgcaagt ggaatttcga 660
ttttcagaat cacaaacccc tagagggcaa gtacgagtgg caagaggtgg agaagggcag 720
cttgcccgag ttctactaca gacccccgcg gccccccaaa ggtgcctgca aggtgccggc 780
gcaggagagc caggatgtca gcgggagccg cccggcggcg cctttaattg gggctccggc 840
taactctgag gacacgcatt tggtggaccc aaagactgat ccgtcggaca gccagacggg 900
gttagcggag caatgcgcag gaataaggaa gcgacctgca accgacgatt cttctactca 960
aaacaaaaga gccaacagaa cagaagaaaa tgtttcagac ggttccccaa atgccggttc 1020
tgtggagcag acgcccaaga agcctggcct cagaagacgt caaacgtaaa cagctcgaat 1080
taagaatatg tttccttgtt tatcagatac atcactgctt gatgaagcaa ggaagatata 1140
catgaaaatt ttaaaaatac atatcgctga cttcatggaa tggacatcct gtataagcac 1200
tgaaaaacaa caacacaata acactaaaat tttaggcact cttaaatgat ctgcctctaa 1260
aagcgttgga tgtagcatta tgcaattagg tttttcctta tttgcttcat tgtactacct 1320
gtgtatatag tttttacctt ttatgtagca cataaacttt ggggaaggga gggcagggtg 1380
gggctgagga actgacgtgg agcggggtat gaagagcttg ctttgattta cagcaagtag 1440
ataaatattt gacttgcatg aagagaagca attttgggga agggtttgaa ttgttttctt 1500
taaagatgta atgtcccttt cagagacagc tgatacttca tttaaaaaaa tcacaaaaat 1560
ttgaacactg gctaaagata attgctattt atttttacaa gaagtttatt ctcatttggg 1620
agatctggtg atctcccaag ctatctaaag tttgttagat agctgcatgt ggctttttta 1680
aaaaagcaac agaaacctat cctcactgcc ctccccagtc tctcttaaag ttggaattta 1740
ccagttaatt actcagcaga atggtgatca ctccaggtag tttggggcaa aaatccgagg 1800
tgcttgggag ttttgaatgt taagaattga ccatctgctt ttattaaatt tgttgacaaa 1860
attttctcat tttcttttca cttcgggctg tgtaaacaca gtcaaaataa ttctaaatcc 1920
ctcgatattt ttaaagatct gtaagtaact tcacattaaa aaatgaaata ttttttaatt 1980
taaagcttac tctgtccatt tatccacagg aaagtgttat ttttcaagga aggttcatgt 2040
agagaaaagc acacttgtag gataagtgaa atggatacta catctttaaa cagtatttca 2100
ttgcctgtgt atggaaaaac catttgaagt gtacctgtgt acataactct gtaaaaacac 2160
tgaaaaatta tactaactta tttatgttaa aagatttttt ttaatctaga caatatacaa 2220
gccaaagtgg catgttttgt gcatttgtaa atgctgtgtt gggtagaata ggttttcccc 2280
tcttttgtta aataatatgg ctatgcttaa aaggttgcat actgagccaa gtataatttt 2340
ttgtaatgtg tgaaaaagat gccaattatt gttacacatt aagtaatcaa taaagaaaac 2400
ttccatagct att 2413
<210>4
<211>600
<212>DNA
<213> chimpanzee (Pan troglodytes SOD2)
<400>4
atgaagcaca gcctccccga cctgccctac gactacggcg ccctggaacc tcacatcaac 60
gcgcagatca tgcagctgca ccacagcaag caccacgcgg cctacgtgaa taacctgaac 120
gtcaccgagg agaagtacca ggaggcgttg gccaagggag atgttacagc ccagatagct 180
cttcagcctg cactgaagtt caatggtggt ggtcatatca atcatagcat tttctggaca 240
aacctcagcc ctaacggtgg tggagaaccc aaaggggagt tgctggaagc catcaaacgt 300
gactttggtt cctttgacaa gtttaaggag aagctgacgg ctgcatctgt tggtgtccaa 360
ggctcaggtt ggggttggct tggtttcaat aaggaacggg gacacttaca aattgctgct 420
tgtccaaatc aggatccact gcaaggaaca acaggcctta ttccactgct ggggattgat 480
gtgtgggagc acgcttacta ccttcagtat aaaaatgtca ggcctgatta tctaaaagct 540
atttggaatg taatcaactg ggagaatgta actgaaagat acatggcttg caaaaagtaa 600
<210>5
<211>3233
<212>DNA
<213> rhesus monkey (Macaca mulatta calcium-sensing receptor)
<220>
<221>misc_feature
<222>(2570)..(2654)
<223>n is a,c,g,or t
<400>5
aaaacttctg ggagcctcca aactcctagc tgtcttgtcc ctcgccctgg agagaaggca 60
gaaccatggc attttattgc tgcttctggg tcctcttggc actcacctgg cacacctctg 120
cctatgggcc cgaccagcga gcccaaaaga aaggggacat tatacttggc gggctctttc 180
ctattcattt tggagtagca gctaaagatc aagatctcaa atcaaggccg gagtctgtgg 240
aatgcatcag gtataatttc cgtgggtttc gctggttaca ggctatgata tttgccatag 300
aggagataaa cagcagccca gcccttcttc ccaacttgac gctgggatac aggatatttg 360
acacttgcaa caccgtttct aaggccttgg aagccaccct gagttttgtt gctcaaaaca 420
aaattgattc tttgaacctt gatgagttct gcaactgctc agagcacatt ccctctacga 480
ttgctgtggt gggagcaact ggctcaggcg tctccacggc agtggcaaat ctgctggggc 540
tcttctacat tccccaggtc agttacgcct cctccagcag actccttagc aacaagaatc 600
aattcaagtc cttcctccga accatcccca atgatgagca ccaggccact gccatggcag 660
acatcattga gtatttccgc tggaactggg tgggcacaat tgcagctgat gatgactatg 720
ggcggccagg gattgagaag ttccgagagg aagctgagga aagggacatc tgcattgact 780
tcagtgaact catctcccag tactctgatg aggaagagat ccagcatgtg gtggaggtga 840
ttcaaaattc cacggccaaa gtaatcgtgg ttttctccag tggcccagac cttgagcccc 900
tcatcaagga gattgtccgg cgcaatatca caggcaagat ctggctggcc agtgaggcct 960
gggccagctc ctccctgatc gccatgcccg agtacttcca cgtggttgga ggcaccattg 1020
gatttgctct gaaggctggg cagatcccag gctttcggga attcctgaag aaggtccatc 1080
ccaggaagtc tgtccacaat ggttttgcca aggagttttg ggaagaaaca tttaactgcc 1140
acctccaaga aggtgccaaa ggacctttac ctgtggacac ctttctgaga ggtcacgaag 1200
aaagtggagg caggtttagc aacagttcga cagccttccg acccctctgt acaggggatg 1260
agaacatcag cagtgttgag accccttaca tagattacac acatttacgg atatcctaca 1320
atgtgtactt agcagtctac tccattgccc atgccttgca agatatatat acctgcttac 1380
ctgggagagg gctcttcacc aacggctcct gtgcagacat caagaaagtt gaggcgtggc 1440
aggtcctgaa gcacctacgg cacctaaact ttaccaacaa tatgggggag caggtgacct 1500
ttgatgagtg tggtgacctg gtggggaact attccatcat caactggcac ctctccccag 1560
aggatggctc catcgtgttt aaggaagtcg ggtattacaa cgtctatgcc aagaagggag 1620
aaagactctt catcaacgag gagaaaatcc tgtggagtgg gttctccagg gaggtgccct 1680
tctccaactg cagccgagac tgtctggcag ggaccaggaa agggatcatt gagggggagc 1740
ccacctgctg ctttgagtgt gtggagtgtc ctgatgggga gtacagcgat gagacagatg 1800
ccagtgcctg taacaagtgc ccagatgact tctggtccaa tgagaaccac acctcctgca 1860
ttgccaagga gatcgagttt ctgtcgtgga cagagccctt tgggattgca ctcaccctct 1920
ttgccgtgct gggcattttc ctgacagcct ttgtgctggg tgtgtttatc aagttccgca 1980
acacgcccat cgtcaaggcc acgaaccgag agctctccta ccttctcctc ttctccctgc 2040
tctgctgctt ctccagctcc ctgttcttca ttggggagcc ccaggactgg acttgccgcc 2100
tgcgccaacc ggcctttggc atcagcttcg tgctctgcat ctcgtgcatc ctggtgaaaa 2160
ccaaccgtgt cctcctggtg tttgaggcca agatccccac cagcttccac cgcaagtggt 2220
gggggctcaa cctgcagttt ctgctggttt tcctctgcac cttcatgcag attgtcatct 2280
gtgtgatctg gctctacacc gcgcccccct caagctaccg caaccacgag ctggaggatg 2340
agatcatctt catcacgtgc cacgagggct cactcatggc cctgggcttc ctgatcggct 2400
acacctgcct gctggctgcc atctgcttct tctttgcctt caagtcccgg aagctgccag 2460
agaacttcaa tgaagccaag ttcatcacct tcagcatgct catcttcttc attgtctgga 2520
tctccttcat tccagcctat gccagcacct acggcaagtt tgtctctgcn nnnnnnnnnn 2580
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2640
nnnnnnnnnn nnnnccatcc cgcaacacca tcgaggaggt gcgttgcagc accgcagctc 2700
acgctttcaa ggtggctgcc cgggccacgc tgcgccgcag caacgtctcc cgcaagcggt 2760
ccagcagcct tgggggctcc actggatcca ccccctcctc ctccatcagc agcaagagca 2820
acagcgaaga cccattccca cagcccgaga ggcagaagca gcagcagccg ctgccaagat 2880
gcaagcagaa ggtcatcttc ggcagtggca cggtcacctt ctcactgagc ttcgatgagc 2940
ctcagaagaa cgccatggcc cacaggaatt ctacacacca gaactccctg gaggcccaga 3000
aaagcagcga tacgctggcc cgacaccagg cattactccc gctgcagtgc ggggaagcgg 3060
actcagatct gagcgtccaa gaaacaggtc tgcaaggacc agtgggtgga gaccaccggc 3120
cagaggtgga ggtccctgaa gagttgtccc cagcacttgt agtgtccagt tcacagagct 3180
ttgtcatcag cggtggagga agcactgtta cagaaaatgt actgcattca taa 3233
<210>6
<211>2694
<212>DNA
<213> dog (Canis BCL2-related)
<400>6
gggggggggg ggccggactc aactctactg tggagtcggg gccatccctc atttttctca 60
ctcaggagcg gctggctggc ggcggctggc tggcggcagg agctggcaat gtttggcctc 120
aagagaaacg cagtaatccg gactcaactc tactgtgggg gggccgggct gggggccggc 180
agcggcggcg cctcctcttc gggagggcgg cttttggctt cggggaggga ggccacgacc 240
agacgggagg gagggggagg ggaagccggt gcggtgattg gcggaagcgc cggcgcaagt 300
cccccgacca ctctggcgcc ggacgcccgg agggtcgcgc ggccctcacc cattggcgct 360
gagggcccca acgtcagcgc gacccccccg aggctgctgc tgctcgcgcc cccctgccgc 420
gcgtcgccgc ctgaagagat ggaaggcccg gccgccgacg ccatcatgtc gcccgaagag 480
gagctagacg ggtacgagcc ggaacctttg gggaagcggc cggcggtcct gcctctgctg 540
gagctggtgg gggaggccag cagtggcccc ggcatggacg gctcgctacc ctcgacgcca 600
cccccggcgg aggaggagga agatgagttg taccggcagt ccctggagat tatctctcgg 660
taccttcggg aacaggccac aggcgccaag gacgcgaaac cactgggcgg gtctcgggcg 720
gccagccgga aggcgttaga gaccctccag cgagtcgggg acggggtaca gcgcaaccac 780
gagacagcct tccaaggcat gcttcggaaa ctggacatca aaaacgaaga cgatgtcaaa 840
tcgttgtctc gagtgattgt ccatgttttc agtgacggag taacaaactg gggcaggatt 900
gtgactctta tttcctttgg tgcctttgtg gccaaacact tgaagagtat aaaccaagaa 960
agctgcatcg aaccattagc agaaagcatc acagatgttc tcgtaaggac gaaacgagac 1020
tggctagtca aacaaagagg ctgggatggg tttgtggagt tcttccatgt agaggaccta 1080
gaaggcggca tcagaaatgt gctgctggct tttgcaggtg ttgctggagt aggagctggt 1140
ttggcatatc taataagata gccttttaag tgcaataatt aacttttaaa caaccccagg 1200
caccaaaacc acatatgact gctgtgaaat caaatgtatt tatgaagttg gactttgagc 1260
tgtccaggct gtaacctcgg agagttctac tctagcaacg tagaaaagca agtggcaaga 1320
ggattatggc taacaggaat aaatacatgg gagaagtagt cccccttgaa gagtcactgt 1380
ctaaaagaag cagagctcag tttcagcaac aggcaaactt ggggaggcca tggaggagga 1440
cttttagatt tagtaaagtt ggtagggttg aagagactta attttcttgt ctagaacagg 1500
agagtggcca gtagccaggc tagtcataga gtccattaaa tatgtccact gaattcatta 1560
acttcccata tagtgttaaa agagaagcac taacaatggc attgatctgt atgaaatgga 1620
tttaagctac aggtgataga actatgacta gaagccgcag tactgtacaa cagtgtgaag 1680
gaaagctttt tctctgtaat tagctttccc aagtatactt cttgaaagtc caagtgctca 1740
ggacgtttta cctgttctac tttggcttgg tttgagtggt ttagtttatt agcctagtaa 1800
tggccaacaa tacttgactt agggtcaata attacaattg caaatgtggg aatagcctca 1860
atttttaagg caaaaacaaa ttataaatgt atttgtctgt aaaaattgtg tatattttta 1920
cagaaagtct atttctttga aatgtaaagg gatgaagagt ctcaaaatat attagttttt 1980
ttttcatgcc cgtttgaaat ttacaacttc tgtagttagg aatctatttc ttacagcttt 2040
tctaaatttt gtcctggtca gttctagatt gtatacagaa ccaattgatg taattgtatg 2100
caacttggtt gtagtggaac aattccaatt cataactatg cagacttttt aattttccta 2160
tctgattggt aagtattctt tagtggtttt gggtgttttg ttttgtttta aacctgggat 2220
tgagaagttg atgaatggaa attcatcctt taacttcatt acatgtgggt ttacaataat 2280
tgagtcaagg tgaagtttga agtttggggg cagggggcgt gtgtgggttg ataacttaaa 2340
aaaataatgg gctctgattg ggcagctact catttgagtt ccttccattt gacctaattt 2400
aactggtgaa atttaaattg agtttatgag ctcatcttca aaacttttgc tagaagattt 2460
tcagctgttc caaatgggac ttactaacag tatgtatata aaaagatcac atcagtggat 2520
gagagacatt tgatcccttg tttgcttaat aaattgtaaa atgatggctt ggaaaagcag 2580
gcttatagtc taaccatggt gctattatta ggcttgcttg ttaaacacag gtctaagcct 2640
agtatatcaa taaaacaaat acttatttca tttgaaaaaa aaaaaaaaaa aaaa 2694
<210>7
<211>3863
<212>DNA
<213> rat (Rattus norvegicus kazrin)
<400>7
ctgcgccgga ggagccggcg cttgccggtg cctgggggtc ggggcgcggg gaaacccggg 60
ccgctggggt gacccaacag gtagagccgg ggccacggcc ggccacgcgc cccccgcgtg 120
catcatgcag ctctttgtca cctctctcgc ccccaggcca aaatcctgag catgatggaa 180
gacaataagc agctcgcgct ccgcatcgat ggggcggtcc agtcggccag ccaggaggtg 240
accaacctgc gagccgaact cacggccacc aaccggagac tggcggaatt gagcggcgga 300
ggcggcggcc ccggctcggg cccgggagct gcgaccagcg cctcggcagc agcggtgacg 360
gtggctgact cggcggtggc gaccatggag aaccatcagc acggagctca agtgctcctg 420
cgggaggaag tggtccagct tcaggaggaa gtccaccttc tccgacagat gaaggaaatg 480
ctggcaaagg acctagagga gtcacagggc ggcaaatgct ccgaggtgct gtcggccact 540
gaactccggg tgcagctggt acagaaggag caggagctgg ccagagccag ggaagccttg 600
caagccatga aagctgaccg gaagcgctta aagggcgaga agaccgacct ggtgagccag 660
atgcagcagt tgtacgccac gctggagagc cgcgaggagc agttgcgaga cttcatccgc 720
aactatgaac aacaccgcaa ggagagtgag gatgctgtca aagcgctggc caaggagaaa 780
gacctgctgg agcgagagaa gtgggagctc cgacggcagg ccaaggaggc cacggaccat 840
gctgcggccc tgcgctccca gctggacctc aaggacaacc gcatgaagga gctggaggcc 900
gagctagcca tggccaagca gtccttagcc acactgacca aggatgttcc caagaggcat 960
tcactcgcca tgcccggcga gacggtgctc aatggcaacc aggaatgggt ggtgcaggct 1020
gacctcccac tgactgccgc catccggcag agccaacaga ctctctacca ctcccaccct 1080
ccccaccctg cagaccgaca agcggtcagg gtgagcccct gccactcaag acagccttcc 1140
gtcatctctg atgcttccgc tgctgaaggt gaccggtcat ctacaccgag cgacatcaac 1200
tccccaagac accggacaca ctccctctgc aacggcgaca gtcccggccc agttcagaag 1260
agcctacaca accctattgt acagtcacta gaggatcttg aagaccaaaa acggaaaaag 1320
aagaaagaga agatgggatt tggctccatc tctcgagtct tcgccagagg gaaacaacgg 1380
aagtccctcg acccgggcct ctttgatggt accgcccctg attattacat agaggaagac 1440
gcggactggt gataacccac cgccctccgc ccgttgtcca cgggcgtgtc tgtgtgtgga 1500
tgagccttgg agagtgtgcg agagtgtgcg tgcgcgtggg gatgcggagc ctgtgtgtgg 1560
ggtgtgtgtg cacggaggca ctcgccctcg tgggtgcgtg tagccaagcg cctggaacag 1620
acagaaacac aaatgtgacc cccaaccccc ctccgcgtcg tcacctctgt aatcgctgta 1680
cataccacaa accgtgtgtg actctgtcaa ccccgttgtc tctgagcgat acacttgtgt 1740
ttgtttctct cgtttgtttt gtttttcgat gttttttggg ggggggggtt gtttgtttgt 1800
ttctgtttaa atccgtcgtg tttttgtttt taatttgccc ctttctcctc cctcctccct 1860
ttttatgaaa cttgaacact tgaaggactg ctgtgtattt gtaaataaca aaagtagtgt 1920
gcactttgtg cttgtaaagt ccctggtcca gccgctactc ctacagccca cgtcgccaag 1980
gacgcgcggt ctgtgtttca tgtcccctcc ttcttcggtg tgaacgtgtg ggaccagacc 2040
ttgttctcgg ggtgtgcccg agtcacttta accacaaaaa cacccccgcc atcgtcgtca 2100
gggtaaggtc actctgcaga gacccgtgag cccatccaag actttttggc tgggccacag 2160
tgtttataag ggggtcatat gggctctttt taatggcctg cctgttttta aattgtgttg 2220
ctgtttcttt ctttatggag caaaaagaga gaaagaaaac ttgcatttaa tttatttgca 2280
caaatgcaga aagcgtattc tatctaaatt attacgtaaa tattggaatg tatatttttc 2340
cacggggtgg gcgggaggcg ggcgtttctg ctgacttgtc tattctgtgt tcatgccgct 2400
gcagacactg tgcaaggtag aattcaggtg gctagagctg gggacctcag acgaccagct 2460
tgcttcttct ttttttctct tttctgtccc cccccccccg gctgctgtcc ctgcatgaga 2520
ggactcccac cttctgctct ggcctttctc tctagatatt ctctctcttt atatatatat 2580
ctatatattt atttatctga catacagatc atgacttcgg tgagcagaga acactaacag 2640
tcaaattccc cttctcttgg acctgtcttt ggaaccatgt tgattgagac aagggaaggt 2700
tagcctgggg cacatctgtg gggtctaacc agacatctgg gcttgagtca gtgggtaaga 2760
ggctcctggt ggcacataca caatgcctct ctatccttag cttattccaa acatagggca 2820
agccagtgtc aacaaagatg atgcccacct tctgggaggg gctgttgggg gcagtatcta 2880
gcaggcaagc cctttgccct ctttcgtcca gttgacttct ttgcccacac atggactttc 2940
tcataatccc tggatccctg tcctctgatt atatcagcga ctcaagcaga ctaagcccaa 3000
aagggctggc aggtgcctgt gcctgtttgt gggggtagca ctgtccctat ggggcctcac 3060
ctggggcatg gagaacccac aagtttccag ccagtaccac cccacccccg aactcagttt 3120
cctctttctc tcctccccat ccccttttaa ctgatcctaa accactaata actcagccca 3180
caccccttat ggccactgct gtgctccctc taacagaaac attctcaact cttgaaagat 3240
ttttcagtac cggatggaaa atctggaatg tataggatct tgtgtccaaa gtctctaaaa 3300
aaacaagcca aaaagcccct caccaggtca cctcttccct cccgacctgg cccagaggcc 3360
ggagagagag caggcaggga caccagatgg gccttcctgg gtacacaaca accctttcgg 3420
ctcagctgat taacccagcc tggtggtgag ggagagaggc cagagctggc atcagaggga 3480
ggtcttagaa aacactaccc ccaccccatg aattttcggg ttttcttttc ctttcttttt 3540
tttatggttc ccccacacac acccttcctt ttaacttaca agaaaataag gttgcaacca 3600
ctcccggtta atggcttagt cactcctctt cgtttcagtt ttttggaaat taggagatta 3660
tcctgtgagt tactaaggat ggtttatttt cgagaaccac atcagatagg gaatgagtta 3720
tgggtaactc tagatgaaaa tgacccttcc cccccccccg ggagaggttt ctcgaaggca 3780
tggatgcaaa atataaaata ttaaaaaaaa gtctaaataa agcttatttt aaaataaaaa 3840
aaaaaaaaaa aaaaaaaaaa agg 3863
<210>8
<211>903
<212>DNA
<213> rat (Rattus Birc5)
<400>8
gatcatgggt gctacggcgc tgcccccgat ctggcagatg taccttaagg accaccggat 60
ctacaccttc aagaactggc ccttcctgga ggattgctcc tgcaccccag agcggatggc 120
ggaggctggc ttcatccact gccctaccga gaatgagcct gatttggccc agtgtttttt 180
ctgctttaag gaactggaag gctgggaacc ggatgacaac cctatagagg agcataggaa 240
gcactcccct ggctgcgcct tccttacagt caagaagcag gtggaagaac tgaccgtcag 300
cgagtttttg aaactggaca aacaaagagc caagaacaaa attgcaaagg agaccaacaa 360
caaacagaaa gagttcgagg agacccggag gaccgtccgg cagtccattg agcagctggc 420
tgccttacgc tgagcctttg ctgggcaacc tggacctgag tgacatgcca cggctaagcc 480
acttgtccca gctttccagg cctgcctggc cgccttggtg tcttacagga gaccgtgaca 540
tttcgaaact ggacgtcaga tgatttgggg ttttgcttta aaggggctca gcctgcgtgg 600
ccacctctct ttggttttgt ggctttgctc tattgtgacc tggacttaag cactgaggaa 660
gggagtggat gagggacagg attctctgac aggatctatg ggtggggagg ggggtgaagg 720
gagggttgtg caaggccttt ctggtcttga tgtttccatg cctggcagct gtcgcagccc 780
atgtgtaggt gttggtttat atatgtttgt gctgataatt cttcttctgt ccttctgatg 840
agtcctccta ccatggggta atggaataaa ataacttaac aaaaaaaaaa aaaaaaaaaa 900
aaa 903
<210>9
<211>8229
<212>DNA
<213> mouse (Mus musculus Pten)
<400>9
gcggcaggat acgcgcttgg gcgtcgggac gcggctgcgc tcagctctct cctctcggaa 60
gctgcagcca tgatggaagt ttgagagttg agccgctgtg aggccaggcc cggcgcaggc 120
gagggagatg agagacggcg gcggccacgg cccagagccc ctctcagcgc ctgtgagcag 180
ccgcgggggc agcgccctcg gggagccggc cgggcggcgg cggcggcagc ggcggcgggc 240
ctcgcctcct cgtcgtctgt tctaaccggg cagcttctga gcagcttcgg agagagacgg 300
tggaagaagc cgtgggctcg agcgggagcc ggcgcaggct cggcggctgc acctcccgct 360
cctggagcgg gggggagaag cggcggcggc ggccgcggct ccggggaggg ggtcggagtc 420
gcctgtcacc attgccaggg ctgggaacgc cggagagttg ctctctcccc ttctcctgcc 480
tccaacacgg cggcggcggc ggcggcacgt ccagggaccc gggccggtgt taagcctccc 540
gtccgccgcc gccgcacccc ccctggcccg ggctccggag gccgccggag gaggcagccg 600
ctgcgaggat tatccgtctt ctccccattc cgctgcctcg gctgccaggc ctctggctgc 660
tgaggagaag caggcccagt ctctgcaacc atccagcagc cgccgcagca gccattaccc 720
ggctgcggtc cagggccaag cggcagcaga gcgaggggca tcagcgaccg ccaagtccag 780
agccatttcc atcctgcaga agaagcctcg ccaccagcag cttctgccat ctctctcctc 840
ctttttcttc agccacaggc tcccagacat gacagccatc atcaaagaga tcgttagcag 900
aaacaaaagg agatatcaag aggatggatt cgacttagac ttgacctata tttatccaaa 960
tattattgct atgggatttc ctgcagaaag acttgaaggt gtatacagga acaatattga 1020
tgatgtagta aggtttttgg attcaaagca taaaaaccat tacaagatat acaatctatg 1080
tgctgagaga cattatgaca ccgccaaatt taactgcaga gttgcacagt atccttttga 1140
agaccataac ccaccacagc tagaacttat caaacccttc tgtgaagatc ttgaccaatg 1200
gctaagtgaa gatgacaatc atgttgcagc aattcactgt aaagctggaa agggacggac 1260
tggtgtaatg atttgtgcat atttattgca tcggggcaaa tttttaaagg cacaagaggc 1320
cctagatttt tatggggaag taaggaccag agacaaaaag ggagtcacaa ttcccagtca 1380
gaggcgctat gtatattatt atagctacct gctaaaaaat cacctggatt acagacccgt 1440
ggcactgctg tttcacaaga tgatgtttga aactattcca atgttcagtg gcggaacttg 1500
caatcctcag tttgtggtct gccagctaaa ggtgaagata tattcctcca attcaggacc 1560
cacgcggcgg gaggacaagt tcatgtactt tgagttccct cagccattgc ctgtgtgtgg 1620
tgatatcaaa gtagagttct tccacaaaca gaacaagatg ctcaaaaagg acaaaatgtt 1680
tcacttttgg gtaaatacgt tcttcatacc aggaccagag gaaacctcag aaaaagtgga 1740
aaatggaagt ctttgtgatc aggaaatcga tagcatttgc agtatagagc gtgcagataa 1800
tgacaaggag tatcttgtac tcaccctaac aaaaaacgat cttgacaaag caaacaaaga 1860
caaggccaac cgatacttct ctccaaattt taaggtgaaa ctatacttta caaaaacagt 1920
agaggagcca tcaaatccag aggctagcag ttcaacttct gtgactccag atgttagtga 1980
caatgaacct gatcattata gatattctga caccactgac tctgatccag agaatgaacc 2040
ttttgatgaa gatcagcatt cacaaattac aaaagtctga tttttttttt cttatcaaga 2100
gggataaaat accatgaaaa aaaaaaaact tgaataaact gaaatggacc tttttttttt 2160
tttttttttt ttaaatggca ataggacatt gtgtcagatt gcagttatag gaacaattct 2220
cttctcctga ccaatcttgt tttaccctat acatccacag ggttttgaca cttgttgtcc 2280
agttaaaaaa aggttgtgta gctgtgtcat gtatatacct ttttgtgtca aaaggacatt 2340
taaaattcaa ttaggataaa taaaagatgg cactttccca ttttattcca gttttataaa 2400
aagtggagac aggctgatgt gtatacgcag gagtttttcc tttattttct gtcaccagct 2460
gaagtggctg aagagctctg attcccgggt tcacgtccta cccctttgca cttgtggcaa 2520
cagataagtt tgcagttggc taaggaagtt tctgcagggt tttgttagat tctaatgcat 2580
gcacttgggt tgggaatgga gggaatgctc agaaaggaat gtttctacct gggctctgga 2640
ccatacacca tctccagctc cttagatgca cctttcttta gcatgctcca cttactaatc 2700
tggacatccg agagattggc tgctgtcctg ctgtttgttt gtgcatttta aagagcatat 2760
tggtgctaga caaggcagct agagtgagta tatttgtagt ggggtacagg aatgaaccat 2820
ctacagcatc ttaagaatcc acaaaggaag ggatataaaa aaagtggtca tagatagata 2880
aaagacacag cagcaatgac ttaaccatac aaatgtggag gctttcaaca aaggatgggc 2940
tggaaacaga aaatttgaca atgatttatt cagtatgctt tctcagttgt aatgactgct 3000
ccatctccta tgtaatcaag gccagtgcta agagtcagat gctattagtc cctacatcag 3060
tcaacacctt acctttattt ttattaattt tcaatcatat acctactgtg gatgcttcat 3120
gtgctggctg ccagtttgtt tttctcctta aatattttat aattcttcac aggaaatttc 3180
aacttgagat tcaacagtaa gcaggttttg tttttttttt ttcctagaga ttgatgatgc 3240
gcgtcctcag tccagtggct gtcagacgtt cagccccttt gaccttacac attctattac 3300
aatgagtttt gcagttttgc acattttttt taaatgtcat taactgttag ggaattttac 3360
ttgaatactg aatacatata atgtgtatat taaaaaagtc attgtttgtg ttaaaaaaga 3420
aattagagtt gcagtaaatt tacagcactg cacgaataat aaggcattga agtttttcag 3480
tagaaattgt cctacagatg ctttatcgac ttgctattgg aagaatagat cttcttaaat 3540
gtgcagtgtt gagtcacttc gttatagtgg tagagttggg attagggctt caattttact 3600
tcttaaatat cattctatgt ttgatatgcc cagactgcat acaatttaaa gcaagagtac 3660
aactactatc gtaatggtaa tgtgaagatg ctattacaaa ggatctcctc ccaacccctc 3720
gggaatttgg tgtctttcaa attatatctt gaccttgaca tttgaatatc cagccattat 3780
tagatttctt aatggtgtga agtcccattt tcaataactt attggtgctg aaattgttca 3840
ctagctgtgg tctgacctag ttaatttaca agtacagatt gcataggacc cactagagaa 3900
gcatttatag tttgatggta agtagattag gcagaacgcc atctaaaata ttcttagaaa 3960
ataatgttga tgtattttcc atacctcatc agtttcactc aaccaataaa gtttttaaaa 4020
ttgtaacaaa gctcttagga tttacacatt tatatttaaa cattgataca tgaatattga 4080
ctgactgttg ataaagtcag agacaacttt tcctgagatc tcaccatgga aatctgtaca 4140
cccccttgtc tttcctaaaa gctgaaagtg gctgactaaa atgcaaagca gctgttgatg 4200
ttttgaagat agtgataaac actgttcttt gttagttttg ggcacagcat gctaaactat 4260
aacttgtatt gttccaatat gtaacacaga gggccaggtc atgaataatg acattacaat 4320
gggctgttgc actgttaata tttttccttt ggaatgtgaa ggtctgaatg agggttttga 4380
ttttgaatgt ttcagtgttt ttgagaagcc ttgcttacat tttatggtgt agtcattgga 4440
aatggaaaaa tggcattata tatatattat atatatataa atatatatat tatacatact 4500
ctccttactt tatttcagtt accatcccca tagaatttga caagaattgc tatgactgaa 4560
agggttttga gtcctaattc aaactttctt tatgacagta ttcacgatta gcctgaagtg 4620
cattctgtag gtgatctctc ccgtgtttct ggaatgcttt cttagactct tggatgtgca 4680
gcagcttatg tgtctgaaat gacttgaagg catcaccttt aagaaggctt acagttgggc 4740
cccgtacatc ccaagtcctc tgtaattcct cttggacatt tttgccataa ttgtaaaagg 4800
gtagttgaat taaatagcgt caccattctt tgctgtggca caggttataa acttaagtgg 4860
agtttaccgg cagcatcaaa tgtttcagct ttaaaaataa aagtaggtta caagttacat 4920
gtttagtttt agaaaatttg tgcaatatgt tcataacgat ggctgtggtt gccacaaagt 4980
gcctcgttta cctttaaata ctgttaatgt gtcgtgcatg cagacggaag gggtggatct 5040
gtgcactaaa cggggggctt ttactctagt attcggcaga gttgccttct acctgccagc 5100
tcaaaagttc gatctgtttt catatagaat atatatacta aaaccatcca gtctgtaaaa 5160
cagccttacc ccgattcagc ctcttcagat actcttgtgc tgtgcagcag tggctctgtg 5220
tgtaaatgct atgcactgag gatacacaaa tatgacgtgt acaggataat gcctcatacc 5280
aatcagatgt ccatttgtta ctgtgtttgt taacaaccct ttatctctta gtgttataaa 5340
ctccacttaa aactgattaa agtctcattc ttgtcattgt gtgggtgttt tattaaatga 5400
gagtatttat aattcaaatt gcttaaatcc attaaaatgt tcagtaatgg gcagccacat 5460
atgattacaa agttcctgtg catttttcta tttttccccc tccttgctat ccttccaagc 5520
aaagcatctt tctgtcatct tggtagacac atacctgtct actcatggtt aagaagagca 5580
ctttaagcct tagtcatcac ttaataagtt attccaggca cagtaaaaag ttcaaggttc 5640
ttggaaaacg gtgcttattt ctcttcttat aagccagatg tctgaagata gccctaaccc 5700
caagaacggg cttgatgtct caggtctgtt ctgtggcttt ctgttttttt taacactgca 5760
gttggccatc agcacatggg aggtttcatc gggacttgtc cagagtagta ggctcaaata 5820
tactatctcc tttctaatat tcttaaaggc taaggagtcc tttcaatata acagtaagat 5880
aacttgtgat gttttagaag taagcagacc attaatgtca atgtggagtc ttaatgttac 5940
atgaagttga tagtttctct gtgacccatt taaaaataca aaccgagtag catgcaatta 6000
tgtaaagaaa tatgaagatt atatgtagtc acacattttc tttagaattc ttagtttggt 6060
gaaaacttga atataaaggt attttgattt atatgacatt ttgatgatat ttgaaaaaaa 6120
ggaatttcct gacattttgc ttttagatca tgtcccccat tgtgctgtaa tttaagccaa 6180
cttggttcag tgaatgccat caccatttcc attgagaatt taaaactcac cagtgtttaa 6240
catgcaggct tctgagggct cccggagaat cagaccttaa gcccagttga tttacttcta 6300
acgtgaaact tcgagttcct gtatactttg ctagataatt tgtggtacat ctaaagctta 6360
gtcttaagtg gcttgtgtgt ggattttatt caacattctt gttgctaggg tagagagaaa 6420
tgttgctgag tagaaacaag agtacccagt tcaatgtggt acagagagca gtccctaaaa 6480
tctgtacaca gtgtaatgga ccactttagg agtcaagagg ctgatttttc ctatgaaatt 6540
acattgcaac aggaagcctt ctagtatagt tccttttact gttagaatat gtttttatgc 6600
atacgctata gctgctttcc catcttccaa caacaggtat caggatgtaa gcaagcttta 6660
aacagtgtga agatggcagg atagtgtcat cggtaacagt cctctgactc taaatgtagt 6720
tgctctgtaa cactttgtga atataacatc acaattctca tgtccttggg gggggggggc 6780
atacccagta ttagtatgtt ttagtgacta agcaatcatt tttctgttta ctcatgtaca 6840
ttttctcttt aaaactaaaa cctgtactgt gtatgtctcc aaagcctttt agcttagttt 6900
ttaggaaatg aacactgaat ggatcacttt ttagtgtagc aggtatggga tatgtgcatt 6960
atagagagac cttgtcagct ctctgggcct atttgaatgt ttattgttgg tgtgaggatg 7020
gtaggggaat cagtaaatac aagttacgtt ggtttagcag agcaagctca gtgtgggtat 7080
ttctctttga agcgtggtgc gtgacgcact gtgagtagag aatttggtca ccctttgagt 7140
cctcttgcat tttgcaaact tgctcagcaa atgcgtacct accttgcccc ctaggtaaaa 7200
gcaggaacta ctactgattt atctgtcact cagctgtctt tatatgtgtg cttctgtgac 7260
ttgtatcaca caagaatctt aaagatttca caaattgtta ccttttagct ctgaatgttg 7320
agtattctgg tgggctaaca acaagacaaa ctcttgacag tcatttgaga attttcatga 7380
aacatttagc tgaaaacatt ttataattta tgaaaaaaat gtgttacctt aaacttttac 7440
atatgtggga gacattaact gccatatttg agcatactga attttaaatt taaaataaag 7500
ctgcatattt ttaaatgaaa tgtttaacaa ggattcatat tttttgtttt ttaagattaa 7560
aaataattta tgtcttctca tgtggaacct catctgtcac aatggttaga ttatacagaa 7620
tggagcaagg cttgtagtgg tttagcttac agtaaaattc ttaatgttta gatgtgttta 7680
cttactggct gttatgtata cttttgagat tttccacctg ttctgtgtag ttttctaaat 7740
gatactccta cttaaaaaca gcattttagt atctattttc tgtctccatt aaatggtcct 7800
cattttctat tgagtttgga agtgtgcaca ttgtgtgtgt gtgtgtgtgt gtgtgtgtgc 7860
acacgtgtgc gcgcccgtgc gtgtgtctat ttgtggagtt tgtatgggag aattagtttt 7920
gaaagtgcta gaatagagat gaaatttggt tcaagtaaaa ttttcccact gggattttac 7980
agtttattgt aataaaatgt taattttgga tgaccttgaa tattaatgaa tttgttagcc 8040
tcttgatgtg tgcattaatg agatatatca aagttgtata ttaaaccaaa gttggagttg 8100
tggaagtgtt tttatgaagt tccgtttggc taccaatgga cataagacta gaaatacctt 8160
cctgtggaga atatttttcc tttaaacaat taaaaaggtt cattattttt gaaaaaaaaa 8220
aaaaaaaaa 8229
<210>10
<211>1329
<212>DNA
<213> aspergillus tubigensis (Aspergillus fumigatus Af293 asparaginase family protein)
<400>10
atgagtcaac cacagagagg tggaggtatc tctgccatct tcgtccatgt aggggcggga 60
tatcacggcc atggaaacga gagagcccac cttcaggtat gcgaaaacgc ttgtaaagcc 120
gcaatgggca ttttaaaaag cggtggatca gctctggatg ctgttgagat ggccatcatt 180
gtaatggagg atgacgagat tacaaatgct ggctatggaa gcaacctgac gattgaagga 240
gctgtcgaat gtgatgctac tattgtcgac caccatggca ggagcggcgc agctggagcc 300
gtctcgccgc gaatgctact tgaaacctct gcaaagcctt taacttgcca cagagtgcct 360
ccaagcttcc tcgttggtga gggtgcaacg gactttgctt atgagcaagg attggtcata 420
ctgcctcctg acgggctcat atcgcgcttt tcgaaagaga gatggcaccg ctggctgcag 480
gatctcgagg ctgctgaact agtcgaaaga aaacgggatc cttcacgttt ccgcatggaa 540
gaagatagag catccttcct tcgtcggcca atgctgaatc gtaatccagc ccgcctcatt 600
gacaatacgc gtttacgccc acatctaccc agctctccct tcaccggagt cgacttgctg 660
aacccccttc ctcgtctcca ggctcttgga agcagacaaa ccatagctcc tgcaccacca 720
gctatgcctt cgaaccaagg acacggcatg ggtcctgcaa ttggacaacc tatggctgtg 780
gcaggtggac aaagtatggc ttctgcacct gagcaaggta tggctgcctc ggccaacacc 840
catgcagatg gtgcgacttt ccgcgcgtgc cctacaaaag caccttgtgc acctgacact 900
tcgacgactg ctcacccggg cgctgcagac gaggatgaag atatgatcag cgatacagtc 960
ggggccatag ctgtagactg ttatggcaat attgcggcag gttcttcgtc tggcgggatt 1020
ggcgcgaagc atcgcggtcg aattgggcct gctgcgctgg tgggcatcgg cacctatgtg 1080
attcctgtgg atcccagcga tcccgaacaa gtatcagtcg cttcagttac atcgggcaca 1140
ggcgagcaca ttgctacaac tatggctgcg cagacgtcag ctgcaagact ctattactgt 1200
caaaagaagt gtaaggacgg tactttcgaa agtgtatccg aagacgaagc tatgaatgca 1260
atcatagcca ctgagttcat gggtgagtta ttgtattcca tattccttac gaccattgat 1320
agagaataa 1329

Claims (7)

1. the small RNA of a modification, it comprises the first fragment and the second fragment, and described the first fragment and the second fragment can form double-stranded region, described the first fragment comprises at least one continuous UA sequence, the continuous UA sequence of the UA sequence complementation that described the second fragment comprises at least one and described the first fragment, the UA sequence of described the first fragment and the UA sequence of described the second fragment form UA/UA site, it is characterized in that, at least one Nucleotide in described UA/UA site is through modifying, this modification makes the stability of the small RNA of modifying higher than the small RNA of unmodified, in the described nucleotide sequence that is modified to small RNA, 2 '-OH of ribose is replaced by methoxyl group or fluorine, Nucleotide in described UA/UA site, other Nucleotide is not through modifying.
2. the small RNA of modification according to claim 1, wherein, the small RNA of this modification comprises multiple UA/UA site, and at least one Nucleotide in the plurality of UA/UA site is through modifying.
3. according to the small RNA of the modification described in any one in claim 1 or 2, wherein, in described UA/UA site, only has a uridylate through modifying.
4. according to the small RNA of the modification described in any one in claim 1 or 2, wherein, the single chain molecule that the small RNA of this modification is hairpin structure, the complementary region between described the first fragment and the second fragment forms double-stranded region.
5. according to the small RNA of the modification described in any one in claim 1 or 2, wherein, the small RNA of this modification comprises positive-sense strand and antisense strand, and described positive-sense strand and antisense strand are continuous nucleotide chain, described first section is positioned at positive-sense strand, and described the second fragment is positioned at antisense strand.
6. according to the small RNA of the modification described in any one in claim 1 or 2, wherein, the small RNA of this modification comprises positive-sense strand and antisense strand, and described positive-sense strand is the discontinuous nucleotide chain that comprises two or more positive-sense strand parts; Described antisense strand is continuous nucleotide chain; Described first section is positioned at one or more positive-sense strand parts, and described the second fragment is positioned at antisense strand.
7. according to the small RNA of the modification described in any one in claim 1 or 2, wherein, the small RNA of this modification is the hybrid molecule that comprises ribonucleotide and at least one deoxyribonucleotide.
CN200910081144.3A 2009-04-03 2009-04-03 Modified small interfering RNA and preparation method thereof Active CN101851618B (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN200910081144.3A CN101851618B (en) 2009-04-03 2009-04-03 Modified small interfering RNA and preparation method thereof
CN201310052144.7A CN103184222B (en) 2009-04-03 2009-04-03 Modified small-interfering ribonucleic acid and preparation method thereof
PCT/CN2010/000405 WO2010111891A1 (en) 2009-04-03 2010-03-30 Modified oligo-nucleic acid molecule, preparation method and uses thereof
EP10757994.8A EP2415869A4 (en) 2009-04-03 2010-03-30 Modified oligo-nucleic acid molecule, preparation method and uses thereof
US13/262,702 US8563710B2 (en) 2009-04-03 2010-03-30 Modified oligonucleotide and its preparation and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910081144.3A CN101851618B (en) 2009-04-03 2009-04-03 Modified small interfering RNA and preparation method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310052144.7A Division CN103184222B (en) 2009-04-03 2009-04-03 Modified small-interfering ribonucleic acid and preparation method thereof

Publications (2)

Publication Number Publication Date
CN101851618A CN101851618A (en) 2010-10-06
CN101851618B true CN101851618B (en) 2014-06-04

Family

ID=42803297

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310052144.7A Active CN103184222B (en) 2009-04-03 2009-04-03 Modified small-interfering ribonucleic acid and preparation method thereof
CN200910081144.3A Active CN101851618B (en) 2009-04-03 2009-04-03 Modified small interfering RNA and preparation method thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310052144.7A Active CN103184222B (en) 2009-04-03 2009-04-03 Modified small-interfering ribonucleic acid and preparation method thereof

Country Status (1)

Country Link
CN (2) CN103184222B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040992A1 (en) 2011-09-20 2013-03-28 苏州瑞博生物技术有限公司 Double-stranded nucleic acid, use and kit thereof in ribonuclease detection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hosgood,H.D,et al..Homo sapiens MIR155 host gene(non-protein coding)(MIR155HG),non-coding RNA.《GENBANK》.2008,第1页. *
Mouldy Sioud,et al..Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs.《Biochemical and Biophysical Research Communication》.2007,第361卷(第1期),122-126. *
许德晖等.高效siRNA设计的研究进展.《遗传》.2006,第28卷(第11期),1457-1461. *

Also Published As

Publication number Publication date
CN103184222B (en) 2015-07-22
CN101851618A (en) 2010-10-06
CN103184222A (en) 2013-07-03

Similar Documents

Publication Publication Date Title
US10233451B2 (en) Method of regulating gene expression
AU2020272668B2 (en) Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias
KR102602047B1 (en) Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
Faria et al. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
AU2020272667B2 (en) Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois
KR20200140853A (en) Use of FUBP1 inhibitors to treat hepatitis B virus infection
CN112708636A (en) Gene transcription framework, vector system, genome sequence editing method and application
US20050196862A1 (en) DNA cassette for cellular expression of small RNA
CN101851619B (en) Modified small RNA and preparation method thereof
WO2003027265A2 (en) Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
CN101851618B (en) Modified small interfering RNA and preparation method thereof
EP2208785A1 (en) Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
Vance et al. Transfection of mouse ribosomal DNA into rat cells: faithful transcription and processing
MISQUITTA et al. Control of sarcoplasmic/endoplasmic-reticulum Ca2+ pump expression in cardiac and smooth muscle
KR100385905B1 (en) Method for high-throughput screening and functional analysis of genes using unigene antisense library
CN103275978B (en) Modified small interfering RNA and preparation method thereof
KR20230093328A (en) Compositions Comprising RNA Guides Targeting B2M and Uses Thereof
CN116648505A (en) Compositions comprising B2M-targeted RNA guides and uses thereof
Leumann Tuning molecular recognition of RNA and DNA via sugar modification
CN115491377A (en) Nucleotide sequence for inducing RNA interference, reducing and eliminating virus pollution in cells and application
CN116981773A (en) Guide RNA for editing polyadenylation signal sequences of target RNA

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOMICS BIOTECHNOLOGIES CO., LTD.

Free format text: FORMER OWNER: BEIJING UNIV.

Effective date: 20111121

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100871 HAIDIAN, BEIJING TO: 226016 NANTONG, JIANGSU PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20111121

Address after: 226016 Jiangsu city of Nantong Province Economic and Technological Development Zone No. 76 Chang Xing Lu

Applicant after: Biomics Biotechnologies Co., Ltd.

Address before: 100871 Beijing the Summer Palace Road, Haidian District, No. 5

Applicant before: Peking University

C14 Grant of patent or utility model
GR01 Patent grant